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Circulating VEGF and eNOS 
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Martina Valgiusti3, Andrea Casadei Gardini3, Luca Maria Neri4, Giovanni Luca Frassineti3, Dino 
Amadori3 & Paola Ulivi1
Novel predictive biomarkers are needed to improve patient selection and optimize the use of 
bevacizumab (B) in metastatic colorectal cancer. We analyzed the potential of five circulating 
biomarkers to predict B efficacy and monitor response. Peripheral blood samples collected at 
baseline, at the first clinical evaluation and at progression were available for 129 patients enrolled in 
the prospective multicentric ITACa trial and randomized to receive FOLFOX4/FOLFIRI (CT) with (64 
patients) or without B (65 patients). VEGF-A, eNOS, EPHB4, COX2 and HIF-1α mRNA levels were 
measured by qRT-PCR. Baseline marker expression levels and their modulation during therapy were 
analyzed in relation to objective response, progression-free survival and overall survival (OS). VEGF and 
eNOS expression was significantly correlated in both groups (Spearman’s correlation coefficient = 0.80; 
P < 0.0001 and 0.75; P < 0.0001, respectively). B-treated patients with >30% reduction in eNOS and 
VEGF levels from baseline to the first clinical evaluation showed better OS than the others (median 
OS 31.6 months, 95% CI 21.3–49.5 months and median OS 14.4 months, 95% CI 9.0–22.7 months, 
respectively, HR 0.38, 95% CI 0.19–0.78, P = 0.008). A reduction in eNOS and VEGF expression from 
baseline to the first clinical evaluation may indicate a response to B.
Bevacizumab (B), a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF-A), 
has proven clinical efficacy when used in first- or second-line treatment in association with fluorouracil-based 
chemotherapy (CT) in metastatic colorectal cancer patients (mCRC)1–3. To date there are no predictive biomark-
ers capable of identifying patients who are most likely to benefit from this treatment4. Plasma or serum con-
centrations of baseline VEGF-A have been analyzed in relation to drug efficacy, but with contrasting results5–8. 
Pretreatment total circulating VEGF-A seems to be prognostic for outcome in mCRC patients, but a predictive 
role for B efficacy has yet to be demonstrated5, 9. An increase in serum VEGF-A concentration after an initial 
decrease has been proposed as a predictive marker of poor response and of reactive resistance to chemotherapy 
plus B10.
We previously described the role of endothelial nitric oxide synthase (eNOS) polymorphisms as possible pre-
dictive biomarkers of B efficacy11 in patients enrolled in the ITACa (Italian Trial in Advanced Colorectal Cancer) 
trial, a prospective randomized phase III multicentric study designed to investigate the role of B treatment in 
mCRC patients12. In particular, patients carrying a specific haplotype combination of 2 eNOS polymorphisms 
(eNOS + 894 G/T and eNOS VNTR 4a/b) showed significantly longer progression-free survival (PFS) and overall 
survival (OS) and a higher overall response rate (ORR) than those with other genotypes11.
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eNOS is a constitutively expressed gene in the endothelium involved in the production of nitric oxide (NO), 
which plays a central role in maintaining endothelial cell functional integrity, regulating hemodynamics, and 
establishing collateral circulation13, 14.
The expression of other biomarkers seems to be correlated with B response. Patients with low ephrin type-B 
receptor 4 (EPHB4) mRNA levels in tumor tissue have a higher response to B than those with high levels15. 
EPHB4 belongs to a large family of receptor tyrosine kinases and mediates arteriovenous differentiation during 
embryonic development, regulating induction and maturation of newly forming vessels in the adult in both phys-
iological and pathological conditions15–17.
Other factors are hypothesized to play a role in determining B sensitivity or resistance. Cyclooxygenase-2 
(COX2) is a key enzyme for inflammatory cytokine-induced angiogenesis18 whose expression levels may conse-
quently influence B activity. Moreover, as hypoxia represents an important event during anti-angiogenic therapy, 
hypoxia inducible factor 1 alpha (HIF-1α) may represent an important prognostic factor during B treatment.
We measured the blood circulating mRNA expression of VEGF-A, eNOS, EPHB4, COX2 and HIF-1α to study 
the predictive role of these markers at baseline and to monitor B efficacy during treatment.
Results
Patient characteristics. The clinical-pathologic characteristics of patients enrolled in the CT + B or CT 
groups are shown in Table 1. Median age was 69 (range 34–83) and 67 years (range 33–82), respectively. Baseline 
patient characteristics were well balanced between groups. One hundred patients had liver metastases (35 had 
liver metastases only and 65 also had extra-hepatic lesions). The remaining 29 patients had only extra-hepatic 
lesions. Median PFS and OS of CT + B patients were 9.6 months (95% confidence intervals [CI], 8.3–12.4) and 
21.4 months (95% CI, 13.9–28.8), respectively, while median PFS and OS of CT patients were 9.1 months (95% 
CI, 8.3–10.4) and 24 months (95% CI, 18.5–28.0), respectively. With regard to tumor localization, 50 patients had 
a right-side tumor and 76 a left-side tumor. Within the right-side group, PFS was significantly higher in CT + B 
patients (12.6 months [95% CI, 8.6–16.0]) compared to CT patients (9.0 months [95% CI, 5.1–10.3] (P = 0.020). 
Patient characteristics
CT + B 
(N = 64) No. 
(%)
CT (N = 65) 
No. (%)
Median age, years (range) 69 (34–83) 67 (33–82)
Gender
 Male 40 (62.5) 35 (53.8)
 Female 24 (37.5) 30 (46.2)
Performance Status (ECOG)
 0 54 (84.4) 53 (81.5)
 1−2 10 (15.6) 12 (18.5)
Tumor localization
 Rectum 20 (31.2) 19 (29.2)
 Colon 44 (68.8) 46 (70.8)
 Right side 26# (41%) 24# (38%)
 Left side 37# (59%) 39# (62%)
Stage at diagnosis
 I–III 14 (21.9) 15 (23.1)
 IV 50 (78.1) 50 (76.9)
Grade
 1 + 2 32 (59.3) 34 (60.7)
 3 22 (40.7) 22 (39.3)
 Unknown/missing 10 9
CT regimen
 FOLFOX4 39 (60.9) 38 (58.5)
 FOLFIRI 25 (39.1) 27 (41.5)
KRAS status*
 Wild type 37 (59.7) 36 (60.0)
 Mutated 25 (40.3) 24 (40.0)
 Unknown/missing 2 5
Prior cancer therapy
 Surgery 51 (79.7) 48 (73.8)
 Radiotherapy 6 (9.4) 6 (9.2)
 Adjuvant chemotherapy 10 (15.6) 9 (13.8)
Table 1. Patient characteristics. CT, chemotherapy; B, bevacizumab. *Required by amendment no. 1 of 3rd May 
2009; #Information about which side of the colon was involved was not available for one patient in the CT + B 
group and 2 patients in the CT group.
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The difference was evident but not significant with regard to OS (27.5 months [95% CI, 15.9–35.7] for CT + B 
vs. 20.3 months [95% CI, 12.1–24.5] for CT) (P = 0.173). No differences were seen in the group of patients with a 
left-side tumor. Median PFS and OS of the entire population were 9.3 months (95% CI, 8.9–10.4) and 22.7 months 
(95% CI, 18.8–27.1), respectively. Median follow-up was 52 months (range 1–77).
Baseline circulating levels of VEGF, eNOS, EPHB4, COX2 and HIF-1α with respect to patient 
outcome. No significant correlation was found between the main clinical-pathologic characteristics of 
patients and median baseline biomarker levels (Supplementary Table S1). There were 37 responders and 25 non 
responders in the CT + B arm, and 38 responders and 27 non responders in the CT group. No statistically sig-
nificant differences were seen between the median baseline biomarker levels of responders and non responders 
(Supplementary Table S2). Furthermore, there were no substantial differences observed between baseline values 
and PFS and OS (Supplementary Table S3).
Circulating biomarker variations during treatment in relation to treatment response. We ana-
lyzed the variation in circulating levels of the 5 biomarkers from baseline to the first clinical evaluation. Within 
the B group, patients with >30% reduction in EPHB4 levels showed a higher rate of response (complete or par-
tial response) than those with no variation. In particular, 24 (75%) of the 32 responders had >30% reduction 
in EPHB4 levels compared to 9 out of 19 (47%) non-responders (P = 0.048). We also observed a trend towards 
significance in the control group (P = 0.064). No substantial differences were seen between other biomarkers and 
response.
Circulating biomarker variations during treatment in relation to patient survival. We evaluated 
PFS and OS on the basis of circulating biomarker changes from baseline to the first clinical evaluation. No signif-
icant differences were observed with respect to PFS. Patients in the B group with ≥30% reduction in eNOS levels 
showed a longer OS than those with <30% reduction (median OS 31.6 months, 95% CI 21.3–42.9 months vs.14.4 
months, 95% CI 11.2–27.5 months, respectively; hazard ratio [HR 0.44], 95% CI 0.21–0.91, P = 0.027) (Table 2 
and Fig. 1A,B). Patients in the same arm with >30% reduction in VEGF levels had a better OS than those with 
<30% reduction (median OS 28.8 months, 95% CI 17.8–42.9 months vs. 15.9 months, 95% CI 8.7–27.5, respec-
tively; HR 0.52, 95% CI 0.27–1.02, P = 0.057) (Table 2 and Fig. 1C,D).
Expression levels of VEGF and eNOS were significantly correlated in both CT + B- and CT groups (Spearman’s 
correlation coefficient = 0.80, P < 0.0001 vs. 0.75, P < 0.0001, respectively). However, in the B group, patients with 
>30% reduction in eNOS or VEGF levels showed a longer OS than the others without this reduction (median 
OS 28.8 months, 95% CI 15.9–42.9 vs. 13.1 months, 95% CI 8.2–22.7, respectively; HR 0.50, 95% CI 0.27–0.91, 
P = 0.023), (Table 3 and Fig. 2A,B).
B-treated patients with >30% reduction in both eNOS and VEGF levels showed longer OS than other 
patients (median OS 31.6 months, 95% CI 21.3–49.5 vs. 14.4 months, 95% CI 9.0–22.7, respectively; HR 0.38, 
95% CI 0.19–0.78, P = 0.008) (Table 3 and Fig. 2C,D). No significant differences were observed in terms of PFS. 
Furthermore, there were no substantial changes in biomarkers expression levels from baseline to progression 
(data not shown).
Discussion
In this study we analyzed the circulating mRNA expression of 5 biomarkers, evaluated at baseline and during B 
treatment, to investigate their potential predictive role. We found that baseline circulating levels of biomarkers 
were not associated with clinical outcome, whereas >30% reduction in eNOS or VEGF levels from baseline to 
the first evaluation was associated with longer OS than in patients with <30% or no reduction. With regard to the 
3 other biomarkers analyzed (HIF-1α, EPHB4 and COX-2), no significant correlations were seen between their 
variations during treatment and patient outcome.
Circulating markers offer a number of advantages over tissue-based markers, including the possibility of car-
rying out continuous and noninvasive assessments over time19, 20. VEGF is the most widely studied biomarker for 
predicting response to antiangiogenic treatment21, 22. An association between the efficacy of antiangiogenic treat-
ments and VEGF tumor levels has been reported in several studies, with contrasting results19, 23, 24. VEGF plasma 
levels at baseline have shown prognostic value and have been correlated with metastatic potential and extension 
of colorectal cancer5, 25, 26. However, as VEGF values are dynamic, their change during treatment may be even 
more relevant than at baseline and could be used as a surrogate biomarker to predict response and progression27. 
This is in agreement with data published data by Gordon et al. who described a reduction in free serum VEGF 
levels in cancer patients treated with escalating doses of an anti-VEGF antibody compared to baseline serum 
concentrations28.
Similarly, Loupakis et al. showed that free VEGF levels measured after immunodepletion of plasma samples 
significantly decreased from baseline to day 14 among mCRC patients receiving B, suggesting that the anti-VEGF 
antibody effectively reduced the plasma level of the biologically active growth factor29. Conversely, other authors 
reported an increase in VEGF after treatment with B8. This discrepancy could be due to the different assays used 
and to the lack of discrimination between free and B-bound VEGF. We measured VEGF mRNA circulating levels 
and found that patients with a reduction in VEGF mRNA levels after B showed a better clinical outcome.
The novelty of our work lies in the measurement of eNOS levels at baseline and during treatment with a 
B-based therapy. As observed for VEGF levels, a >30% reduction in eNOS levels was associated with a better 
prognosis. Moreover, patients showing >30% reduction in both VEGF and eNOS levels showed longer sur-
vival, suggesting that the inhibition of both proteins indicates a better response to the antiangiogenic treat-
ment. Interestingly, no significant association with survival was found in the CT-only group, reinforcing the 
predictive value of a reduction in biomarker levels in relation to B efficacy. Given that these two biomarkers were 
www.nature.com/scientificreports/
4Scientific RepoRts | 7: 1293  | DOI:10.1038/s41598-017-01420-0
Biomarker 
change
No. 
patients
PFS (months) OS (months)
No. 
events
Median 
value 
(95% 
CI)
HR 
(95% 
CI) P
No. 
events
Median 
value 
(95% 
CI)
HR 
(95% 
CI) P
CT + B
 VEGF-A <30% 24 20
8.8 
(6.1–
12.5)
1.00 19
15.9 
(8.7–
27.5)
1.00
 ≥30% 27 24
11.9 
(9.1–
15.7)
0.86 
(0.47–
1.58)
0.637 17
28.8 
(17.8–
42.9)
0.52 
(0.27–
1.02)
0.057
 COX-2 <30% 11 8
18.7 
(6.1–
41.7)
1.00 6
41.7 
(6.8–
47.1)
1.00
 ≥30% 40 36
9.9 
(8.6–
12.4)
2.00 
(0.88–
4.54)
0.097 30
21.3 
(14.6–
28.8)
1.57 
(0.64–
3.84)
0.319
 HIF-1α <30% 21 17
9.1 
(6.2–
25.1)
1.00 16
20.1 
(11.2–
33.1)
1.00
 ≥30% 30 27
11.4 
(9.1–
14.9)
1.11 
(0.59–
2.07)
0.752 20
25.2 
(14.4–
36.7)
0.93 
(0.47–
1.87)
0.849
 EPHB4 <30% 21 17
9.1 
(6.1–
15.9)
1.00 16
19.3 
(8.7–
33.1)
1.00
 ≥30% 30 27
10.8 
(9.1–
14.9)
1.01 
(0.54–
1.87)
0.983 20
25.2 
(14.6–
36.7)
0.64 
(0.33–
1.25)
0.189
 eNOS <30% 33 28
9.1 
(6.8–
10.2)
1.00 24
14.4 
(11.2–
27.5)
1.00
 ≥30% 18 16
14.1 
(10.6–
18.7)
0.66 
(0.35–
1.23)
0.191 12
31.6 
(21.3–
42.9)
0.44 
(0.21–
0.91)
0.027
CT
 VEGF-A <30% 30 27
9.1 
(7.4–
10.4)
1.00 22
23.2 
(16.6–
29.1)
1.00
 ≥30% 27 25
11.4 
(8.9–
15.0)
0.76 
(0.44–
1.32)
0.326 19
26.4 
(20.2–
30.2)
0.83 
(0.45–
1.53)
0.545
 COX-2 <30% 20 20
8.9 
(6.3–
9.5)
1.00 17
23.2 
(16.6–
28.0)
1.00
 ≥ 30% 37 32
11.4 
(9.0–
15.0)
0.41 
(0.22–
0.75)
0.004 24
26.4 
(20.2–
36.7)
0.66 
(0.35–
1.23)
0.194
 HIF-1α <30% 26 24
9.0 
(6.5–
9.3)
1.00 21
22.0 
(14.4–
28.6)
1.00
 ≥30% 31 28
12.1 
(9.0–
16.2)
0.62 
(0.36–
1.08)
0.092 20
26.5 
(20.4–
30.2)
0.72 
(0.39–
1.34)
0.302
 EPHB4 <30% 24 23
8.9 
(6.5–
9.5)
1.00 19
20.8 
(16.6–
27.1)
1.00
 ≥30% 33 29
11.4 
(9.0–
16.2)
0.52 
(0.29–
0.92)
0.024 22
28.0 
(20.4–
30.2)
0.66 
(0.36–
1.23)
0.192
 eNOS <30% 33 30
9.3 
(8.9–
13.0)
1.00 22
27.1 
(18.8–
36.6)
1.00
 ≥30% 24 22
10.3 
(6.0–
12.1)
1.26 
(0.72–
2.19)
0.420 19
23.2 
(15.0–
29.2)
1.32 
(0.71–
2.44)
0.379
Table 2. PFS and OS with respect to changes in biomarker levels from baseline to first clinical evaluation. 
PFS, progression-free survival; OS, overall survival; CT, chemotherapy; B, bevacizumab; HR, hazard ratio; CI, 
confidence interval.
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Figure 1. Patient flow diagram.
No. 
patients
PFS (months) OS (months)
No. 
events
Median 
PFS 
(95% 
CI)
HR 
(95% 
CI) P
No. 
events
Median 
OS 
(95% 
CI)
HR 
(95% 
CI) P
CT + B
 Other 23 19
8.1 
(4.5–
10.2)
1.00 18
13.1 
(8.2–
22.7)
1.00
 eNOS or VEGF 
reduction ≥ 30% 28 25
11.9 
(9.2–
15.9)
0.68 
(0.40–
1.16)
0.161 18
28.8 
(15.9–
42.9)
0.50 
(0.27–
0.91)
0.023
 Other 34 29
9.0 
(6.1–
10.2)
1.00 25
14.4 
(9.0–
22.7)
1.00
 eNOS and VEGF 
reduction ≥30% 17 15
12.6 
(9.2–
22.3)
0.59 
(0.32–
1.07)
0.083 11
31.6 
(21.3–
49.5)
0.38 
(0.19–
0.78)
0.008
CT
 Other 24 21
9.1 
(7.4–
10.0)
1.00 17
18.8 
(14.0–
28.0)
1.00
 eNOS or VEGF 
reduction ≥30% 33 31
10.3 
(7.2–
12.2)
0.90 
(0.54–
1.50)
0.696 24
24.3 
(20.0–
29.6)
0.76 
(0.43–
1.34)
0.342
 Other 39 36
9.0 
(7.4–
9.6)
1.00 27
20.8 
(17.1–
28.0)
1.00
 eNOS and VEGF 
reduction ≥30% 18 16
11.4 
(8.9–
15.0)
0.79 
(0.45–
1.41)
0.430 14
24.3 
(15.0–
30.2)
0.89 
(0.48–
1.65)
0.705
Table 3. Reduction in eNOS and/or VEGF levels with respect to PFS/OS. PFS, progression-free survival; OS, 
overall survival; HR, hazard ratio; CI, confidence interval; CT, chemotherapy; B, bevacizumab.
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significantly correlated with each other and that their reduction was associated with better outcome, we can 
hypothesized that the VEGF-VEGFR-eNOS pathway may be involved in the response to B-based therapy.
In a previous work we demonstrated that a specific eNOS haplotype combination (defined as eNOS Haplo1/
Haplo1 and eNOS Haplo 2/Haplo2) was associated with a favorable outcome in terms of ORR, PFS and OS in 
mCRC patients treated with B11. We also evaluated eNOS level changes with respect to different eNOS genotypes. 
A substantial percentage of patients carrying the eNOS haplotype combination responded to B-based therapy, a 
high number of these showing >30% reduction in eNOS levels. Conversely, fewer than half of the patients car-
rying other eNOS genotypes responded to treatment, and a small number of these also showed >30% reduction 
in eNOS levels (data not shown). These findings are suggestive of the potential role of eNOS pathway during B 
treatment.
Our study is somewhat limited by its small sample size and requires further validation in a prospective, inde-
pendent and larger case series. However, the results were obtained on a prospectively enrolled patient population 
treated homogeneously in a randomized, prospective phase III multicenter study (ITACa trial) featuring two 
treatment arms: CT + B vs. CT only.
In conclusion, mCRC patients with a concomitant reduction in VEGF and eNOS biomarker levels showed a 
better outcome to treatment, indicating that these biomarkers might be useful to monitor B efficacy.
Methods
Patients and sample collection. This study included patients enrolled in the ITACa clinical trial12. 
Participation in the ITACa biological study was not mandatory for those taking part in the clinical trial. Of the 
376 patients with mCRC enrolled in the ITACa trial, 129 had sufficient blood samples to be considered for this 
planned secondary analysis. Inclusion criteria, the randomization strategy and clinical results are described 
elsewhere12. Patients were randomized to receive first-line CT (FOLFOX4 or FOLFIRI) only or CT + B. CT + B 
doses and treatment details can be found in the original study article12. Sixty-four patients received CT + B 
and 65 patients received CT only (control group). Peripheral blood samples were collected in PAXgene tubes 
(PreAnalytix-Qiagen, Hilden, Germany) at various time points during the trial: at baseline (before the start of 
treatment), at the first evaluation (about 2 months later) and at disease progression (PD). Blood samples for 129 
patients were available for analysis at baseline, for 108 (84%) at the first clinical evaluation and for 77 (60%) at PD 
(Fig. 3). Data were collected in accordance with good clinical practice.
All patients were evaluated for response, PFS and OS, in accordance with RECIST criteria version 1.1. Tumor 
response was assessed every 8 weeks by computed tomography. Responders included patients who obtained a 
complete response (CR) or partial response (PR). Non responders included those with stable disease (SD) or PD. 
The study was approved by the Local Ethics Committee (Ethics Committee Area Vasta Romagna and IRST) and 
Figure 2. OS with respect to reduction in eNOS levels in CT + B (A) and CT (B) groups, and with respect to 
VEGF reduction in CT + B (C) and CT (D) groups.
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informed consent for the use of biological material for research purposes was obtained from all patients before 
blood sample collection. The study was approved by the Local Ethics Committee (Ethics Committee Area Vasta 
Romagna and IRST) and informed consent for the use of biological material for research purposes was obtained 
from all patients before blood sample collection. All samples were collected in accordance with relevant guide-
lines and regulations.
RNA extraction and amplification. Analyses of VEGF-A, COX2, HIF-1α, EPHB4 and eNOS were 
performed by biologists blinded to patient outcome. Total RNA was extracted by PAX-Gene blood RNA kit 
(PreAnalytix-Qiagen, Hilden, Germany) and RNA was treated with DNAse I. Five hundred nanograms of RNA 
were reverse-transcribed using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). The final reverse 
transcription mixture was incubated at 25 °C for 5 min, at 42 °C for 30 min and at 85 °C for 5 min. Real-time PCR 
was performed using the 7500 Applied Biosystems and TaqMan assay chemistry (Gene expression Assay, Applied 
Biosystems, Foster City, CA, USA). Two stably expressed endogenous β2-microglobulin (B2M) and hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) genes were selected by Genorm software v. 3.230 and were amplified and 
used as reference genes. All the RT-PCR experiments were run in duplicate.
Statistical analysis. Gene expression analyses were performed by Applied Biosystems qPCR software. 
mRNA levels were normalized to endogenous reference B2M and HPRT genes. We used a healthy donor as cali-
brator. Relative quantification was calculated by the 2-delta delta Ct method. The aims of this planned secondary 
analysis were to examine the association between baseline circulating mRNA expression of VEGF-A, eNOS, 
EPHB4, COX2 and HIF-1α and PFS and OS in the ITACa population, and to investigate their variation during 
treatment in order to monitor B efficacy. We chose the median value of variation in the case series (30%) as the 
cut-off.
The primary aim of the ITACa study was PFS. Secondary efficacy endpoints were ORR and OS. PFS was 
calculated as the time from the date of randomization to the date of the first observation of PD (per investigator 
assessment), last tumor evaluation or death in the absence of progressive disease. Patients undergoing curative 
metastasectomy were censored at the time of surgery. OS was calculated as the time from the date of randomiza-
tion to the date of death from any cause or last follow-up.
Descriptive statistics were used to describe enrolled patients. The relationship between baseline mRNA 
expression of VEGF-A, eNOS, EPHB4, COX2 and HIF-1α and clinical-pathologic factors was analyzed using 
a nonparametric ranking statistic (Median test). Spearman’s correlation coefficient was used to investigate the 
relationship between the mRNA levels considered as continuous variables.
Time to event data (PFS, OS) were described using the Kaplan-Meier method and compared using the log 
rank test (at a significance level of 5%). 95% CIs were calculated by nonparametric methods. Estimated HRs and 
their 95% CI were calculated by the Cox regression model. We also conducted landmark analysis to reduce the 
potential for time-dependent confounding in treatment by assessing the impact of changes in mRNA levels from 
baseline to the first tumor evaluation (about 2 months after the start of treatment) on survival outcome. Patients 
Figure 3. OS with respect to reduced eNOS or VEGF levels and reduced eNOS and VEGF levels in patients 
treated with CT + B ((A,C) respectively) or CT ((B,D) respectively).
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who were still alive and had not been lost to follow-up at the landmark time were divided into two categories on 
the basis of whether they had progressed or not by that time. PFS and OS after the landmark time were computed 
with Kaplan-Meier curves.
The correlation between circulating mRNA expression of VEGF-A, eNOS, EPHB4, COX2 and HIF-1α and 
clinical outcome was analyzed separately in each treatment group (CT + B and CT). All P-values were based on 
two-sided testing and statistical analyses were carried out using SAS statistical software version 9.4 (SAS Institute, 
Cary, NC, USA).
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